Lupin's Generic Lotemax SM Exclusivity & Launch

  Published 1 year ago

Lupin secures 180-day exclusivity for generic Lotemax SM gel in the U.S., set to launch from India's Pithampur facility.

  • Product treats post-op eye inflammation and pain, with $29M annual U.S. sales in May 2025.
  • Lupin, a global pharma leader, distributes in 100+ markets, offering branded, generic, and biotech products.
  • Manufactured at Pithampur, India, the gel is a corticosteroid with complex formulation expertise.

You might like these

India Reviews Banking Rules & Foreign Investment

ITD Cementation India: Engineering Excellence in Infrastructure

P&G CFO Resignation and New Leadership Announcement

MPS Appoints Sreenivas for Global Growth & Innovation

Paytm Rises Ahead of Q1 Results

Pakistan's 2025, 26 Budget: Defense Hike, Growth Goals, IMF Challenges

Poonawalla Fincorp Launches Business Loan 24/7 for MSMEs

News that matters the most ⚡